{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:05:13Z","timestamp":1784297113909,"version":"3.55.0"},"publisher-location":"Cham","reference-count":283,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032031754","type":"print"},{"value":"9783032031761","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-03176-1_18","type":"book-chapter","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:48:23Z","timestamp":1762984103000},"page":"363-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis"],"prefix":"10.1007","author":[{"given":"Shabnam","family":"Varmazyari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Borhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Moradipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heliya","family":"Ziaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"Suppl 3","key":"18_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/eji.201970400","volume":"3","author":"17th International Congress of Immunology","year":"2019","unstructured":"17th International Congress of Immunology (2019) 17th international congress of immunology, 19-23 October 2019, Beijing, China. Eur J Immunol 3(Suppl 3):1\u20132223. https:\/\/doi.org\/10.1002\/eji.201970400","journal-title":"Eur J Immunol"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"175628481879355","DOI":"10.1177\/1756284818793558","volume":"11","author":"A Acovic","year":"2018","unstructured":"Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V (2018) Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Ther Adv Gastroenterol 11:1756284818793558. https:\/\/doi.org\/10.1177\/1756284818793558","journal-title":"Ther Adv Gastroenterol"},{"issue":"6","key":"18_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","volume":"25","author":"NI Affara","year":"2014","unstructured":"Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25(6):809\u2013821. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.026","journal-title":"Cancer Cell"},{"issue":"11","key":"18_CR4","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.4049\/jimmunol.157.11.4762","volume":"157","author":"ML Alegre","year":"1996","unstructured":"Alegre ML, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, Thompson CB (1996) Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 157(11):4762\u20134770","journal-title":"J Immunol"},{"key":"18_CR5","doi-asserted-by":"publisher","unstructured":"\u00c1lvarez-Teijeiro S, Garc\u00eda-Incl\u00e1n C, Villaronga M, Casado P, Hermida-Prado F, Granda-D\u00edaz R, Rodrigo JP, Calvo F, Del-R\u00edo-Ibisate N, Gandarillas A, Mor\u00eds F, Hermsen M, Cutillas P, Garc\u00eda-Pedrero JM (2018) Factors secreted by cancer-associated fibroblasts that sustain cancer stem properties in head and neck squamous carcinoma cells as potential therapeutic targets. Cancers (Basel) 10(9). https:\/\/doi.org\/10.3390\/cancers10090334","DOI":"10.3390\/cancers10090334"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3389\/fimmu.2019.03095","volume":"10","author":"K Anderson","year":"2019","unstructured":"Anderson K, Ryan N, Volpedo G, Varikuti S, Satoskar AR, Oghumu S (2019) Immune suppression mediated by STAT4 deficiency promotes lymphatic metastasis in HNSCC. Front Immunol 10:3095. https:\/\/doi.org\/10.3389\/fimmu.2019.03095","journal-title":"Front Immunol"},{"issue":"2","key":"18_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2009.12.019","volume":"17","author":"P Andreu","year":"2010","unstructured":"Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, Coussens LM (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17(2):121\u2013134. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.019","journal-title":"Cancer Cell"},{"issue":"8","key":"18_CR8","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/1078-0432.Ccr-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R et al (2014) A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 20(8):2192\u20132204. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2200","journal-title":"Clin Cancer Res"},{"issue":"1","key":"18_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41408-024-01173-w","volume":"14","author":"S Ansell","year":"2024","unstructured":"Ansell S, Bhardwaj V, Yang Z-Z, Jalali S, Villasboas J, Mudappathi R, Wang J, Mukherjee P, Paludo J, Tang X, Kim H, Krull J, Wenzl K, Novak A, Mondello P (2024) Expanded tumor-associated polymorphonuclear Myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity. Blood Cancer J 14(1):217","journal-title":"Blood Cancer J"},{"issue":"8","key":"18_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/bjc.2014.446","volume":"111","author":"P Balermpas","year":"2014","unstructured":"Balermpas P, R\u00f6del F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, Harter PN, Mittelbronn M, Weiss C, R\u00f6del C, Fokas E (2014) Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer 111(8):1509\u20131518. https:\/\/doi.org\/10.1038\/bjc.2014.446","journal-title":"Br J Cancer"},{"issue":"6","key":"18_CR11","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/jci76264","volume":"124","author":"JE Bauman","year":"2014","unstructured":"Bauman JE, Grandis JR (2014) Targeting secondary immune responses to cetuximab: CD137 and the outside story. J Clin Invest 124(6):2371\u20132375. https:\/\/doi.org\/10.1172\/jci76264","journal-title":"J Clin Invest"},{"key":"18_CR12","doi-asserted-by":"publisher","first-page":"1001161","DOI":"10.3389\/fimmu.2022.1001161","volume":"13","author":"H Baysal","year":"2022","unstructured":"Baysal H, Siozopoulou V, Zaryouh H, Hermans C, Lau HW, Lambrechts H, Fransen E, De Pauw I, Jacobs J, Peeters M, Pauwels P, Vermorken JB, Smits E, Lardon F, De Waele J, Wouters A (2022) The prognostic impact of the immune signature in head and neck squamous cell carcinoma. Front Immunol 13:1001161. https:\/\/doi.org\/10.3389\/fimmu.2022.1001161","journal-title":"Front Immunol"},{"key":"18_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fimmu.2020.00275","volume":"11","author":"A Ben-Shmuel","year":"2020","unstructured":"Ben-Shmuel A, Biber G, Barda-Saad M (2020) Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy? Front Immunol 11:275. https:\/\/doi.org\/10.3389\/fimmu.2020.00275","journal-title":"Front Immunol"},{"issue":"10","key":"18_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737\u2013744. https:\/\/doi.org\/10.1038\/35036374","journal-title":"Nat Cell Biol"},{"issue":"18","key":"18_CR15","doi-asserted-by":"publisher","first-page":"26307","DOI":"10.18632\/oncotarget.8368","volume":"7","author":"U Bharadwaj","year":"2016","unstructured":"Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ (2016) Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 7(18):26307\u201326330. https:\/\/doi.org\/10.18632\/oncotarget.8368","journal-title":"Oncotarget"},{"issue":"1","key":"18_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41392-020-00419-w","volume":"6","author":"AA Bhat","year":"2021","unstructured":"Bhat AA, Yousuf P, Wani NA, Rizwan A, Chauhan SS, Siddiqi MA, Bedognetti D, El-Rifai W, Frenneaux MP, Batra SK, Haris M, Macha MA (2021) Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduct Target Ther 6(1):12. https:\/\/doi.org\/10.1038\/s41392-020-00419-w","journal-title":"Signal Transduct Target Ther"},{"key":"18_CR17","doi-asserted-by":"publisher","unstructured":"Birbrair A (2020) tumor microenvironments in organs from the brain to the skin \u2013 part A: from the brain to the skin \u2013 part A. https:\/\/doi.org\/10.1007\/978-3-030-36214-0","DOI":"10.1007\/978-3-030-36214-0"},{"key":"18_CR18","unstructured":"Blacher E, Levy A, Baruch BB, Green KD, Garneau-Tsodikova S, Fridman M, Stein R (2015) Targeting CD38 in the tumor microenvironment; a novel approach to treat glioma. Cancer Cell Microenviron 2"},{"key":"18_CR19","volume-title":"Cancer vaccines: from research to clinical practice","author":"A Bot","year":"2011","unstructured":"Bot A, Obrocea M, Marincola F, Farsaci B (2011) Cancer vaccines: from research to clinical practice. CRC Press"},{"issue":"1\u20132","key":"18_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1582-4934.2008.00650.x","volume":"14","author":"J Boucek","year":"2010","unstructured":"Boucek J, Mrkvan T, Chovanec M, Kuchar M, Betka J, Boucek V, Hladikova M, Betka J, Eckschlager T, Rihova B (2010) Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med 14(1\u20132):426\u2013433. https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00650.x","journal-title":"J Cell Mol Med"},{"issue":"1","key":"18_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","volume":"10","author":"I Brana","year":"2015","unstructured":"Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E (2015) Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol 10(1):111\u2013123. https:\/\/doi.org\/10.1007\/s11523-014-0320-2","journal-title":"Target Oncol"},{"issue":"4","key":"18_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.otc.2021.04.004","volume":"54","author":"ZS Buchwald","year":"2021","unstructured":"Buchwald ZS, Schmitt NC (2021) Immunotherapeutic strategies for head and neck cancer. Otolaryngol Clin N Am 54(4):729\u2013742. https:\/\/doi.org\/10.1016\/j.otc.2021.04.004","journal-title":"Otolaryngol Clin N Am"},{"issue":"1","key":"18_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-023-02943-5","volume":"23","author":"HS Budi","year":"2023","unstructured":"Budi HS, Farhood B (2023) Targeting oral tumor microenvironment for effective therapy. Cancer Cell Int 23(1):101. https:\/\/doi.org\/10.1186\/s12935-023-02943-5","journal-title":"Cancer Cell Int"},{"issue":"4","key":"18_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.4049\/jimmunol.170.4.1822","volume":"170","author":"TN Bullock","year":"2003","unstructured":"Bullock TN, Mullins DW, Engelhard VH (2003) Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 170(4):1822\u20131829. https:\/\/doi.org\/10.4049\/jimmunol.170.4.1822","journal-title":"J Immunol"},{"key":"18_CR25","doi-asserted-by":"publisher","unstructured":"Buoncervello M, Gabriele L, Toschi E (2019) The Janus face of tumor microenvironment targeted by immunotherapy. Int J Mol Sci 20(17). https:\/\/doi.org\/10.3390\/ijms20174320","DOI":"10.3390\/ijms20174320"},{"key":"18_CR26","doi-asserted-by":"crossref","unstructured":"Burcher KM, Burcher JT, Inscore L, Bloomer CH, Furdui CM, Porosnicu M (2022) A review of the role of oral microbiome in the development, detection, and management of head and neck squamous cell cancers. Cancers 14(17)","DOI":"10.3390\/cancers14174116"},{"issue":"7501","key":"18_CR27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","volume":"289","author":"FM Burnet","year":"1967","unstructured":"Burnet FM (1967) Immunological aspects of malignant DiseasE. Lancet 289(7501):1171\u20131174. https:\/\/doi.org\/10.1016\/S0140-6736(67)92837-1","journal-title":"Lancet"},{"issue":"1","key":"18_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111\u2013122. https:\/\/doi.org\/10.1016\/j.immuni.2007.05.016","journal-title":"Immunity"},{"issue":"1","key":"18_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.Ccr-14-1716","volume":"21","author":"JA Califano","year":"2015","unstructured":"Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM et al (2015) Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21(1):30\u201338. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1716","journal-title":"Clin Cancer Res"},{"issue":"11","key":"18_CR30","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","volume":"184","author":"C Camisaschi","year":"2010","unstructured":"Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184(11):6545\u20136551. https:\/\/doi.org\/10.4049\/jimmunol.0903879","journal-title":"J Immunol"},{"key":"18_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fcell.2019.00052","volume":"7","author":"M Canning","year":"2019","unstructured":"Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, Cui Y (2019) Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol 7:52. https:\/\/doi.org\/10.3389\/fcell.2019.00052","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"18_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S1665-2681(19)31885-X","volume":"7","author":"D Cervantes-Garc\u00eda","year":"2008","unstructured":"Cervantes-Garc\u00eda D, Ortiz-L\u00f3pez R, Mayek-P\u00e9rez N, Rojas-Mart\u00ednez A (2008) Oncolytic virotherapy. Ann Hepatol 7(1):34\u201345","journal-title":"Ann Hepatol"},{"issue":"15","key":"18_CR33","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1073\/pnas.96.15.8603","volume":"96","author":"CA Chambers","year":"1999","unstructured":"Chambers CA, Kuhns MS, Allison JP (1999) Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci USA 96(15):8603\u20138608. https:\/\/doi.org\/10.1073\/pnas.96.15.8603","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7637","key":"18_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"issue":"2","key":"18_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18(2):99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1","journal-title":"Nat Rev Drug Discov"},{"key":"18_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45. https:\/\/doi.org\/10.1186\/s12916-015-0278-7","journal-title":"BMC Med"},{"issue":"9","key":"18_CR37","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.Cd-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J et al (2018) CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov 8(9):1156\u20131175. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1033","journal-title":"Cancer Discov"},{"issue":"7","key":"18_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/mc.23162","volume":"59","author":"SMY Chen","year":"2020","unstructured":"Chen SMY, Krinsky AL, Woolaver RA, Wang X, Chen Z, Wang JH (2020) Tumor immune microenvironment in head and neck cancers. Mol Carcinog 59(7):766\u2013774. https:\/\/doi.org\/10.1002\/mc.23162","journal-title":"Mol Carcinog"},{"issue":"7","key":"18_CR39","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1158\/1078-0432.Ccr-06-1586","volume":"13","author":"AA Chiappori","year":"2007","unstructured":"Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O\u2019Bryant C et al (2007) A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 13(7):2091\u20132099. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1586","journal-title":"Clin Cancer Res"},{"issue":"12","key":"18_CR40","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","volume":"47","author":"YA Cho","year":"2011","unstructured":"Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD (2011) Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 47(12):1148\u20131153. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.08.007","journal-title":"Oral Oncol"},{"issue":"32","key":"18_CR41","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/jco.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A et al (2016) Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34(32):3838\u20133845. https:\/\/doi.org\/10.1200\/jco.2016.68.1478","journal-title":"J Clin Oncol"},{"issue":"623","key":"18_CR42","doi-asserted-by":"publisher","first-page":"eabf8495","DOI":"10.1126\/scitranslmed.abf8495","volume":"13","author":"CA Chuckran","year":"2021","unstructured":"Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F et al (2021) Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med 13(623):eabf8495. https:\/\/doi.org\/10.1126\/scitranslmed.abf8495","journal-title":"Sci Transl Med"},{"issue":"5","key":"18_CR43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.Can-15-2001","volume":"76","author":"F Concha-Benavente","year":"2016","unstructured":"Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL (2016) Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFN\u03b3 that induce PD-L1 expression in head and neck cancer. Cancer Res 76(5):1031\u20131043. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-2001","journal-title":"Cancer Res"},{"issue":"11","key":"18_CR44","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2010) HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439\u20132453. https:\/\/doi.org\/10.1084\/jem.20100587","journal-title":"J Exp Med"},{"key":"18_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104460","volume":"99","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Ferris RL (2019) Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 99:104460. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104460","journal-title":"Oral Oncol"},{"key":"18_CR46","doi-asserted-by":"crossref","unstructured":"Cristina V, Herrera-G\u00f3mez RG, Szturz P, Espeli V, Siano M (2019) Immunotherapies and future combination strategies for head and neck squamous cell carcinoma. Int J Mol Sci 20(21)","DOI":"10.3390\/ijms20215399"},{"issue":"2","key":"18_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.seminoncol.2014.03.003","volume":"41","author":"JM Curry","year":"2014","unstructured":"Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-ad V, Pribitkin E, Tuluc M (2014) Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 41(2):217\u2013234. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.03.003","journal-title":"Semin Oncol"},{"key":"18_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-030-49270-0_6","volume":"1273","author":"RE Dadey","year":"2020","unstructured":"Dadey RE, Workman CJ, Vignali DAA (2020) Regulatory T cells in the tumor microenvironment. Adv Exp Med Biol 1273:105\u2013134. https:\/\/doi.org\/10.1007\/978-3-030-49270-0_6","journal-title":"Adv Exp Med Biol"},{"key":"18_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41199-016-0013-x","volume":"1","author":"RJ Davis","year":"2016","unstructured":"Davis RJ, Ferris RL, Schmitt NC (2016) Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. Cancers Head Neck 1:12. https:\/\/doi.org\/10.1186\/s41199-016-0013-x","journal-title":"Cancers Head Neck"},{"issue":"37","key":"18_CR50","doi-asserted-by":"publisher","first-page":"60860","DOI":"10.18632\/oncotarget.18486","volume":"8","author":"MC de Medeiros","year":"2017","unstructured":"de Medeiros MC, Banerjee R, Liu M, Anovazzi G, D\u2019Silva NJ, Junior CR (2017) HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation. Oncotarget 8(37):60860\u201360874. https:\/\/doi.org\/10.18632\/oncotarget.18486","journal-title":"Oncotarget"},{"issue":"5","key":"18_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccr.2005.04.014","volume":"7","author":"KE de Visser","year":"2005","unstructured":"de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411\u2013423. https:\/\/doi.org\/10.1016\/j.ccr.2005.04.014","journal-title":"Cancer Cell"},{"issue":"6","key":"18_CR52","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6):1257\u20131265. https:\/\/doi.org\/10.1084\/jem.20062512","journal-title":"J Exp Med"},{"issue":"6","key":"18_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000480","volume":"5","author":"J Delaloye","year":"2009","unstructured":"Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5(6):e1000480. https:\/\/doi.org\/10.1371\/journal.ppat.1000480","journal-title":"PLoS Pathog"},{"issue":"6","key":"18_CR54","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.31534","volume":"143","author":"W-W Deng","year":"2018","unstructured":"Deng W-W, Li Y-C, Ma S-R, Mao L, Yu G-T, Bu L-L, Kulkarni AB, Zhang W-F, Sun Z-J (2018) Specific blockade CD73 alters the \u201cexhausted\u201d phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer 143(6):1494\u20131504. https:\/\/doi.org\/10.1002\/ijc.31534","journal-title":"Int J Cancer"},{"issue":"4","key":"18_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40290-019-00288-x","volume":"33","author":"K Devaraja","year":"2019","unstructured":"Devaraja K (2019) Current prospects of molecular therapeutics in head and neck squamous cell carcinoma. Pharmaceut Med 33(4):269\u2013289. https:\/\/doi.org\/10.1007\/s40290-019-00288-x","journal-title":"Pharmaceut Med"},{"issue":"4","key":"18_CR56","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/ijc.29046","volume":"136","author":"K Dobrenis","year":"2015","unstructured":"Dobrenis K, Gauthier LR, Barroca V, Magnon C (2015) Granulocyte colony-stimulating factor off-target effect on nerve outgrowth promotes prostate cancer development. Int J Cancer 136(4):982\u2013988. https:\/\/doi.org\/10.1002\/ijc.29046","journal-title":"Int J Cancer"},{"issue":"1","key":"18_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s40425-019-0728-4","volume":"7","author":"S Dorta-Estremera","year":"2019","unstructured":"Dorta-Estremera S, Hegde VL, Slay RB, Sun R, Yanamandra AV, Nicholas C, Nookala S, Sierra G, Curran MA, Sastry KJ (2019) Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer. J Immunother Cancer 7(1):252. https:\/\/doi.org\/10.1186\/s40425-019-0728-4","journal-title":"J Immunother Cancer"},{"key":"18_CR58","doi-asserted-by":"publisher","unstructured":"Echarti A, Hecht M, B\u00fcttner-Herold M, Haderlein M, Hartmann A, Fietkau R, Distel L (2019) CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer. Cancers (Basel) 11(9). https:\/\/doi.org\/10.3390\/cancers11091398","DOI":"10.3390\/cancers11091398"},{"key":"18_CR59","doi-asserted-by":"publisher","unstructured":"Economopoulou P, Kotsantis I, Psyrri A (2020) Tumor microenvironment and immunotherapy response in head and neck cancer. Cancers (Basel) 12(11). https:\/\/doi.org\/10.3390\/cancers12113377","DOI":"10.3390\/cancers12113377"},{"issue":"3","key":"18_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161\u2013174. https:\/\/doi.org\/10.1038\/nrc745","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"18_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s1074-7613(01)00259-x","volume":"16","author":"JG Egen","year":"2002","unstructured":"Egen JG, Allison JP (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16(1):23\u201335. https:\/\/doi.org\/10.1016\/s1074-7613(01)00259-x","journal-title":"Immunity"},{"issue":"7","key":"18_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis GI, Sheppard NC, Riley JL (2021) Genetic engineering of T cells for immunotherapy. Nat Rev Genet 22(7):427\u2013447. https:\/\/doi.org\/10.1038\/s41576-021-00329-9","journal-title":"Nat Rev Genet"},{"issue":"1","key":"18_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","volume":"13","author":"A Elmusrati","year":"2021","unstructured":"Elmusrati A, Wang J, Wang CY (2021) Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci 13(1):24. https:\/\/doi.org\/10.1038\/s41368-021-00131-7","journal-title":"Int J Oral Sci"},{"key":"18_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9794-7_1","volume":"2058","author":"CE Engeland","year":"2020","unstructured":"Engeland CE, Bell JC (2020) Introduction to oncolytic Virotherapy. Methods Mol Biol 2058:1\u20136. https:\/\/doi.org\/10.1007\/978-1-4939-9794-7_1","journal-title":"Methods Mol Biol"},{"issue":"2","key":"18_CR65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj\/mn\/7800123","volume":"9","author":"MJ Eppihimer","year":"2002","unstructured":"Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP (2002) Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9(2):133\u2013145. https:\/\/doi.org\/10.1038\/sj\/mn\/7800123","journal-title":"Microcirculation"},{"issue":"7355","key":"18_CR66","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475(7355):226\u2013230. https:\/\/doi.org\/10.1038\/nature10169","journal-title":"Nature"},{"key":"18_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-031-27156-4_7","volume":"185","author":"M Fatima","year":"2023","unstructured":"Fatima M, Amraiz D, Navid MT (2023) Oncolytic Virotherapy. Cancer Treat Res 185:105\u2013126. https:\/\/doi.org\/10.1007\/978-3-031-27156-4_7","journal-title":"Cancer Treat Res"},{"issue":"10","key":"18_CR68","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1002\/hed.26329","volume":"42","author":"RM Ferrandino","year":"2020","unstructured":"Ferrandino RM, Roof S, Garneau J, Haidar Y, Bates SE, Park YA, Bauml JM, Genden EM, Miles B, Sigel K (2020) Neutrophil-to-lymphocyte ratio as a prognostic indicator for overall and cancer-specific survival in squamous cell carcinoma of the head and neck. Head Neck 42(10):2830\u20132840. https:\/\/doi.org\/10.1002\/hed.26329","journal-title":"Head Neck"},{"issue":"2","key":"18_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000137669","volume":"29","author":"FO Ferreira","year":"2008","unstructured":"Ferreira FO, Ribeiro FL, Batista AC, Leles CR et al (2008) Association of CCL2 with lymph node metastasis and macrophage infiltration in oral cavity and lip squamous cell carcinoma. Tumour Biol 29(2):114\u2013121. https:\/\/doi.org\/10.1159\/000137669","journal-title":"Tumour Biol"},{"issue":"29","key":"18_CR70","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/jco.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33(29):3293\u20133304. https:\/\/doi.org\/10.1200\/jco.2015.61.1509","journal-title":"J Clin Oncol"},{"key":"18_CR71","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1200\/JCO.2016.34.15_suppl.6009","volume":"34","author":"R Ferris","year":"2016","unstructured":"Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Haddad R, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M (2016) Further evaluations of nivolumab (nivo) versus investigator\u2019s choice (IC) chemotherapy for recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol 34:6009\u20136009. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.6009","journal-title":"J Clin Oncol"},{"issue":"1","key":"18_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R (2019) Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer 18(1):70. https:\/\/doi.org\/10.1186\/s12943-019-0994-2","journal-title":"Mol Cancer"},{"key":"18_CR73","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fonc.2018.00310","volume":"8","author":"MD Forster","year":"2018","unstructured":"Forster MD, Devlin MJ (2018) Immune checkpoint inhibition in head and neck cancer. Front Oncol 8:310. https:\/\/doi.org\/10.3389\/fonc.2018.00310","journal-title":"Front Oncol"},{"issue":"7","key":"18_CR74","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034. https:\/\/doi.org\/10.1084\/jem.192.7.1027","journal-title":"J Exp Med"},{"issue":"3","key":"18_CR75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell 16(3):183\u2013194. https:\/\/doi.org\/10.1016\/j.ccr.2009.06.017","journal-title":"Cancer Cell"},{"issue":"2","key":"18_CR76","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3892\/or.2020.7628","volume":"44","author":"E Fu","year":"2020","unstructured":"Fu E, Liu T, Yu S, Chen X, Song L, Lou H, Ma F, Zhang S, Hussain S, Guo J, Sun J, Yu P, Mao X, Wei L (2020) M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF. Oncol Rep 44(2):698\u2013710. https:\/\/doi.org\/10.3892\/or.2020.7628","journal-title":"Oncol Rep"},{"issue":"10","key":"18_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1226719","volume":"5","author":"CW Fugle","year":"2016","unstructured":"Fugle CW, Zhang Y, Hong F, Sun S, Westwater C, Rachidi S, Yu H, Garret-Mayer E, Kirkwood K, Liu B, Li Z (2016) CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells. Onco Targets Ther 5(10):e1226719. https:\/\/doi.org\/10.1080\/2162402x.2016.1226719","journal-title":"Onco Targets Ther"},{"key":"18_CR78","doi-asserted-by":"publisher","unstructured":"Fulop T, Franceschi C, Hirokawa K, Pawelec G (2019) Handbook of immunosenescence basic understanding and clinical implications: basic understanding and clinical implications. https:\/\/doi.org\/10.1007\/978-3-319-99375-1","DOI":"10.1007\/978-3-319-99375-1"},{"issue":"1","key":"18_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.Cir-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0297","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"18_CR80","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253\u2013268. https:\/\/doi.org\/10.1038\/nri3175","journal-title":"Nat Rev Immunol"},{"key":"18_CR81","doi-asserted-by":"publisher","unstructured":"Gao XH, Chen HD (2016) Practical immunodermatology. https:\/\/doi.org\/10.1007\/978-94-024-0902-4","DOI":"10.1007\/978-94-024-0902-4"},{"issue":"52","key":"18_CR82","doi-asserted-by":"publisher","first-page":"87037","DOI":"10.18632\/oncotarget.13523","volume":"7","author":"L Gao","year":"2016","unstructured":"Gao L, Wang FQ, Li HM, Yang JG, Ren JG, He KF, Liu B, Zhang W, Zhao YF (2016) CCL2\/EGF positive feedback loop between cancer cells and macrophages promotes cell migration and invasion in head and neck squamous cell carcinoma. Oncotarget 7(52):87037\u201387051. https:\/\/doi.org\/10.18632\/oncotarget.13523","journal-title":"Oncotarget"},{"issue":"1","key":"18_CR83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K (2017) Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer 5(1):71. https:\/\/doi.org\/10.1186\/s40425-017-0277-7","journal-title":"J Immunother Cancer"},{"key":"18_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101977","volume":"84","author":"N Gavrielatou","year":"2020","unstructured":"Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A (2020) Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 84:101977. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101977","journal-title":"Cancer Treat Rev"},{"key":"18_CR85","doi-asserted-by":"publisher","unstructured":"Gavrielatou N, Vathiotis I, Economopoulou P, Psyrri A (2021) The role of B cells in head and neck cancer. Cancers (Basel) 13(21). https:\/\/doi.org\/10.3390\/cancers13215383","DOI":"10.3390\/cancers13215383"},{"issue":"3","key":"18_CR86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.20010938","volume":"195","author":"F Gerosa","year":"2002","unstructured":"Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195(3):327\u2013333. https:\/\/doi.org\/10.1084\/jem.20010938","journal-title":"J Exp Med"},{"issue":"16","key":"18_CR87","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.febslet.2014.02.005","volume":"588","author":"FG Giancotti","year":"2014","unstructured":"Giancotti FG (2014) Deregulation of cell signaling in cancer. FEBS Lett 588(16):2558\u20132570. https:\/\/doi.org\/10.1016\/j.febslet.2014.02.005","journal-title":"FEBS Lett"},{"key":"18_CR88","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/82_2010_114","volume":"344","author":"MV Goldberg","year":"2011","unstructured":"Goldberg MV, Drake CG (2011) LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 344:269\u2013278. https:\/\/doi.org\/10.1007\/82_2010_114","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"18_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639","volume":"45","author":"NH Goradel","year":"2021","unstructured":"Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B (2021) Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer 45(1):100639. https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100639","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"18_CR90","first-page":"2794","volume":"6","author":"JR Grandis","year":"2000","unstructured":"Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA (2000) Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 6(7):2794\u20132802","journal-title":"Clin Cancer Res"},{"issue":"6","key":"18_CR91","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/1078-0432.Ccr-19-2625","volume":"26","author":"S Greene","year":"2020","unstructured":"Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C (2020) Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models. Clin Cancer Res 26(6):1420\u20131431. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2625","journal-title":"Clin Cancer Res"},{"issue":"11","key":"18_CR92","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","volume":"182","author":"JF Grosso","year":"2009","unstructured":"Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182(11):6659\u20136669. https:\/\/doi.org\/10.4049\/jimmunol.0804211","journal-title":"J Immunol"},{"key":"18_CR93","doi-asserted-by":"publisher","unstructured":"Hamada M, Yura Y (2020) Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer. Int J Mol Sci 21(19). https:\/\/doi.org\/10.3390\/ijms21197073","DOI":"10.3390\/ijms21197073"},{"issue":"17\u201318","key":"18_CR94","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1089\/hum.2023.122","volume":"34","author":"F Hamdan","year":"2023","unstructured":"Hamdan F, Fusciello M, Cerullo V (2023) Personalizing oncolytic Virotherapy. Hum Gene Ther 34(17\u201318):870\u2013877. https:\/\/doi.org\/10.1089\/hum.2023.122","journal-title":"Hum Gene Ther"},{"issue":"8","key":"18_CR95","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"6","key":"18_CR96","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/14712598.2015.1036737","volume":"15","author":"J Honeychurch","year":"2015","unstructured":"Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM (2015) Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther 15(6):787\u2013801. https:\/\/doi.org\/10.1517\/14712598.2015.1036737","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"18_CR97","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.trecan.2019.02.007","volume":"5","author":"JD Horton","year":"2019","unstructured":"Horton JD, Knochelmann HM, Day TA, Paulos CM, Neskey DM (2019) Immune evasion by head and neck cancer: foundations for combination therapy. Trends Cancer 5(4):208\u2013232. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.007","journal-title":"Trends Cancer"},{"issue":"5","key":"18_CR98","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2217\/fon.14.306","volume":"11","author":"P Hu","year":"2015","unstructured":"Hu P, Wang G, Shen M, Zhang P, Zhang J, Du J, Liu Q (2015) Intratumoral polymorphonuclear granulocyte is associated with poor prognosis in squamous esophageal cancer by promoting epithelial-mesenchymal transition. Future Oncol 11(5):771\u2013783. https:\/\/doi.org\/10.2217\/fon.14.306","journal-title":"Future Oncol"},{"issue":"16","key":"18_CR99","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1158\/0008-5472.Can-15-2664","volume":"76","author":"Y Hu","year":"2016","unstructured":"Hu Y, Lu L, Xia Y, Chen X, Chang AE, Hollingsworth RE, Hurt E, Owen J, Moyer JS, Prince ME, Dai F, Bao Y, Wang Y, Whitfield J, Xia JC, Huang S, Wicha MS, Li Q (2016) Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Res 76(16):4661\u20134672. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-2664","journal-title":"Cancer Res"},{"issue":"2","key":"18_CR100","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.Can-05-1299","volume":"66","author":"B Huang","year":"2006","unstructured":"Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66(2):1123\u20131131. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-1299","journal-title":"Cancer Res"},{"issue":"17","key":"18_CR101","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1073\/pnas.95.17.10067","volume":"95","author":"AA Hurwitz","year":"1998","unstructured":"Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95(17):10067\u201310071. https:\/\/doi.org\/10.1073\/pnas.95.17.10067","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"18_CR102","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444\u20132448","journal-title":"Cancer Res"},{"issue":"6","key":"18_CR103","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.13415","volume":"72","author":"JF Jardim","year":"2018","unstructured":"Jardim JF, Gondak R, Galvis MM, Pinto CAL, Kowalski LP (2018) A decreased peritumoral CD1a+ cell number predicts a worse prognosis in oral squamous cell carcinoma. Histopathology 72(6):905\u2013913. https:\/\/doi.org\/10.1111\/his.13415","journal-title":"Histopathology"},{"issue":"2","key":"18_CR104","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","volume":"177","author":"AG Jarnicki","year":"2006","unstructured":"Jarnicki AG, Lysaght J, Todryk S, Mills KHG (2006) Suppression of antitumor immunity by IL-10 and TGF-\u03b2-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T Cells1. J Immunol 177(2):896\u2013904. https:\/\/doi.org\/10.4049\/jimmunol.177.2.896","journal-title":"J Immunol"},{"issue":"10","key":"18_CR105","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"HB Jie","year":"2013","unstructured":"Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL (2013) Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109(10):2629\u20132635. https:\/\/doi.org\/10.1038\/bjc.2013.645","journal-title":"Br J Cancer"},{"issue":"11","key":"18_CR106","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.Can-14-2788","volume":"75","author":"HB Jie","year":"2015","unstructured":"Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL (2015) CTLA-4+ regulatory T cells increased in Cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75(11):2200\u20132210. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-2788","journal-title":"Cancer Res"},{"issue":"4","key":"18_CR107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"18_CR108","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239\u2013252. https:\/\/doi.org\/10.1038\/nrc2618","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"18_CR109","doi-asserted-by":"publisher","first-page":"19310","DOI":"10.18632\/oncotarget.14242","volume":"8","author":"G Karpathiou","year":"2017","unstructured":"Karpathiou G, Casteillo F, Giroult JB, Forest F, Fournel P, Monaya A, Froudarakis M, Dumollard JM, Prades JM, Peoc\u2019h M (2017) Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. Oncotarget 8(12):19310\u201319322. https:\/\/doi.org\/10.18632\/oncotarget.14242","journal-title":"Oncotarget"},{"issue":"19","key":"18_CR110","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838\u20131847. https:\/\/doi.org\/10.1056\/NEJMoa0810097","journal-title":"N Engl J Med"},{"issue":"8","key":"18_CR111","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/sj.bjc.6605891","volume":"103","author":"R Kesselring","year":"2010","unstructured":"Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B (2010) Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 103(8):1245\u20131254. https:\/\/doi.org\/10.1038\/sj.bjc.6605891","journal-title":"Br J Cancer"},{"key":"18_CR112","doi-asserted-by":"publisher","first-page":"6058147","DOI":"10.1155\/2016\/6058147","volume":"2016","author":"J Kim","year":"2016","unstructured":"Kim J, Bae JS (2016) Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm 2016:6058147. https:\/\/doi.org\/10.1155\/2016\/6058147","journal-title":"Mediat Inflamm"},{"issue":"1","key":"18_CR113","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/jca.5112","volume":"4","author":"S Koontongkaew","year":"2013","unstructured":"Koontongkaew S (2013) The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 4(1):66\u201383. https:\/\/doi.org\/10.7150\/jca.5112","journal-title":"J Cancer"},{"key":"18_CR114","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2021.03.005","volume":"149","author":"M Kuksin","year":"2021","unstructured":"Kuksin M, Morel D, Aglave M, Danlos FX, Marabelle A, Zinovyev A, Gautheret D, Verlingue L (2021) Applications of single-cell and bulk RNA sequencing in onco-immunology. Eur J Cancer 149:193\u2013210. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.005","journal-title":"Eur J Cancer"},{"issue":"5","key":"18_CR115","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.Ccr-06-1726","volume":"13","author":"J Kurai","year":"2007","unstructured":"Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13(5):1552\u20131561. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1726","journal-title":"Clin Cancer Res"},{"issue":"1","key":"18_CR116","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.1038\/s41467-021-27619-4","volume":"12","author":"CHL K\u00fcrten","year":"2021","unstructured":"K\u00fcrten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA et al (2021) Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun 12(1):7338. https:\/\/doi.org\/10.1038\/s41467-021-27619-4","journal-title":"Nat Commun"},{"issue":"1","key":"18_CR117","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1084\/jem.20061852","volume":"204","author":"K Lahl","year":"2007","unstructured":"Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G et al (2007) Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 204(1):57\u201363. https:\/\/doi.org\/10.1084\/jem.20061852","journal-title":"J Exp Med"},{"issue":"19","key":"18_CR118","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/1078-0432.Ccr-17-3726","volume":"24","author":"S Lang","year":"2018","unstructured":"Lang S, Bruderek K, Kaspar C, H\u00f6ing B, Kanaan O, Dominas N, Hussain T, Droege F, Eyth C, Hadaschik B, Brandau S (2018) Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin Cancer Res 24(19):4834\u20134844. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3726","journal-title":"Clin Cancer Res"},{"issue":"3","key":"18_CR119","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261\u2013268. https:\/\/doi.org\/10.1038\/85330","journal-title":"Nat Immunol"},{"issue":"5256","key":"18_CR120","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734\u20131736. https:\/\/doi.org\/10.1126\/science.271.5256.1734","journal-title":"Science"},{"issue":"3","key":"18_CR121","doi-asserted-by":"publisher","first-page":"1535293","DOI":"10.1080\/2162402x.2018.1535293","volume":"8","author":"A Lechner","year":"2019","unstructured":"Lechner A, Schl\u00f6\u00dfer HA, Thelen M, Wennhold K, Rothschild SI, Gilles R, Quaas A, Siefer OG, Huebbers CU, Cukuroglu E, G\u00f6ke J, Hillmer A, Gathof B, Meyer MF, Klussmann JP, Shimabukuro-Vornhagen A, Theurich S, Beutner D, von Bergwelt-Baildon M (2019) Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Onco Targets Ther 8(3):1535293. https:\/\/doi.org\/10.1080\/2162402x.2018.1535293","journal-title":"Onco Targets Ther"},{"issue":"8","key":"18_CR122","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.4049\/jimmunol.1300606","volume":"191","author":"C Lee-Chang","year":"2013","unstructured":"Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel R, de Cabo R, Biragyn A (2013) Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol 191(8):4141\u20134151. https:\/\/doi.org\/10.4049\/jimmunol.1300606","journal-title":"J Immunol"},{"issue":"1","key":"18_CR123","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tripleo.2010.11.032","volume":"112","author":"C Li","year":"2011","unstructured":"Li C, Zhao Y, Zhang W, Zhang W (2011) Increased prevalence of T(H)17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(1):81\u201389. https:\/\/doi.org\/10.1016\/j.tripleo.2010.11.032","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"18_CR124","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200324228","volume":"33","author":"SC Liang","year":"2003","unstructured":"Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33(10):2706\u20132716. https:\/\/doi.org\/10.1002\/eji.200324228","journal-title":"Eur J Immunol"},{"issue":"1","key":"18_CR125","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T (2023) Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther 8(1):156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"18_CR126","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793\u2013801. https:\/\/doi.org\/10.1016\/s1074-7613(94)80021-9","journal-title":"Immunity"},{"issue":"3","key":"18_CR127","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/mc.22767","volume":"57","author":"JF Liu","year":"2018","unstructured":"Liu JF, Deng WW, Chen L, Li YC, Wu L, Ma SR, Zhang WF, Bu LL, Sun ZJ (2018a) Inhibition of JAK2\/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Mol Carcinog 57(3):429\u2013439. https:\/\/doi.org\/10.1002\/mc.22767","journal-title":"Mol Carcinog"},{"issue":"1","key":"18_CR128","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","volume":"37","author":"JF Liu","year":"2018","unstructured":"Liu JF, Wu L, Yang LL, Deng WW, Mao L, Wu H, Zhang WF, Sun ZJ (2018b) Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res 37(1):44. https:\/\/doi.org\/10.1186\/s13046-018-0713-7","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"18_CR129","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1158\/1078-0432.Ccr-17-1350","volume":"24","author":"Z Liu","year":"2018","unstructured":"Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL (2018c) Novel effector phenotype of Tim-3(+) regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clin Cancer Res 24(18):4529\u20134538. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-1350","journal-title":"Clin Cancer Res"},{"key":"18_CR130","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D, Andl T, Zhang Y (2019) Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 7:60. https:\/\/doi.org\/10.3389\/fcell.2019.00060","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"18_CR131","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12672-024-00870-z","volume":"15","author":"S Liu","year":"2024","unstructured":"Liu S, Wang R, Fang J (2024) Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. Discov Oncol 15(1):22. https:\/\/doi.org\/10.1007\/s12672-024-00870-z","journal-title":"Discov Oncol"},{"issue":"11","key":"18_CR132","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-009-0697-4","volume":"58","author":"A L\u00f3pez-Albaitero","year":"2009","unstructured":"L\u00f3pez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL (2009) Role of polymorphic fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58(11):1853\u20131864. https:\/\/doi.org\/10.1007\/s00262-009-0697-4","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"18_CR133","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/vaccines2040841","volume":"2","author":"CT Lucido","year":"2014","unstructured":"Lucido CT, Vermeer PD, Wieking BG, Vermeer DW, Lee JH (2014) CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. Vaccines (Basel) 2(4):841\u2013853. https:\/\/doi.org\/10.3390\/vaccines2040841","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"18_CR134","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","volume":"16","author":"SR Ma","year":"2017","unstructured":"Ma SR, Deng WW, Liu JF, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ (2017a) Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer 16(1):99. https:\/\/doi.org\/10.1186\/s12943-017-0665-0","journal-title":"Mol Cancer"},{"issue":"26","key":"18_CR135","doi-asserted-by":"publisher","first-page":"42061","DOI":"10.18632\/oncotarget.14939","volume":"8","author":"X Ma","year":"2017","unstructured":"Ma X, Sheng S, Wu J, Jiang Y, Gao X, Cen X, Wu J, Wang S, Tang Y, Tang Y, Liang X (2017b) LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma. Oncotarget 8(26):42061\u201342075. https:\/\/doi.org\/10.18632\/oncotarget.14939","journal-title":"Oncotarget"},{"issue":"1","key":"18_CR136","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, Wang Q, Yang M, Kalady MF, Qian J, Zhang A, Gupte AA, Hamilton DJ, Zheng C, Yi Q (2019) Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab 30(1):143\u2013156.e145. https:\/\/doi.org\/10.1016\/j.cmet.2019.04.002","journal-title":"Cell Metab"},{"issue":"7","key":"18_CR137","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1325066","volume":"6","author":"D Maggioni","year":"2017","unstructured":"Maggioni D, Pignataro L, Garavello W (2017) T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma. Onco Targets Ther 6(7):e1325066. https:\/\/doi.org\/10.1080\/2162402x.2017.1325066","journal-title":"Onco Targets Ther"},{"issue":"12","key":"18_CR138","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, Lyssiotis C, Liu JR, Kryczek I, Zou W (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18(12):1332\u20131341. https:\/\/doi.org\/10.1038\/ni.3868","journal-title":"Nat Immunol"},{"issue":"17","key":"18_CR139","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal R, \u015eenbabao\u011flu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1(17):e89829. https:\/\/doi.org\/10.1172\/jci.insight.89829","journal-title":"JCI Insight"},{"issue":"5","key":"18_CR140","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ijc.31115","volume":"142","author":"L Mao","year":"2018","unstructured":"Mao L, Zhao ZL, Yu GT, Wu L, Deng WW, Li YC, Liu JF, Bu LL, Liu B, Kulkarni AB, Zhang WF, Zhang L, Sun ZJ (2018) \u03b3-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma. Int J Cancer 142(5):999\u20131009. https:\/\/doi.org\/10.1002\/ijc.31115","journal-title":"Int J Cancer"},{"key":"18_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105472","volume":"121","author":"L Mao","year":"2021","unstructured":"Mao L, Xiao Y, Yang QC, Yang SC, Yang LL, Sun ZJ (2021) TIGIT\/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. Oral Oncol 121:105472. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105472","journal-title":"Oral Oncol"},{"issue":"12","key":"18_CR142","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/cncr.20701","volume":"101","author":"B Marcus","year":"2004","unstructured":"Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD, Teknos TN (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101(12):2779\u20132787. https:\/\/doi.org\/10.1002\/cncr.20701","journal-title":"Cancer"},{"issue":"1","key":"18_CR143","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/cancers7010382","volume":"7","author":"SM Markwell","year":"2015","unstructured":"Markwell SM, Weed SA (2015) Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion. Cancers (Basel) 7(1):382\u2013406. https:\/\/doi.org\/10.3390\/cancers7010382","journal-title":"Cancers (Basel)"},{"issue":"4","key":"18_CR144","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4065\/83.4.489","volume":"83","author":"S Marur","year":"2008","unstructured":"Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83(4):489\u2013501. https:\/\/doi.org\/10.4065\/83.4.489","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"18_CR145","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3892\/etm.2021.10562","volume":"22","author":"L Mazilu","year":"2021","unstructured":"Mazilu L, Suceveanu AI, Stanculeanu DL, Gheorghe AD, Fricatel G, Negru SM (2021) Tumor microenvironment is not an \u2018innocent bystander\u2019 in the resistance to treatment of head and neck cancers (review). Exp Ther Med 22(4):1128. https:\/\/doi.org\/10.3892\/etm.2021.10562","journal-title":"Exp Ther Med"},{"issue":"9","key":"18_CR146","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00262-021-03001-7","volume":"70","author":"SL McArdel","year":"2021","unstructured":"McArdel SL, Dugast AS, Hoover ME, Bollampalli A, Hong E, Castano Z, Leonard SC, Pawar S, Mellen J, Muriuki K, McLaughlin DC, Bayhi N, Carpenter CL, Turka LA, Wickham TJ, Elloul S (2021) Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15. Cancer Immunol Immunother 70(9):2701\u20132719. https:\/\/doi.org\/10.1007\/s00262-021-03001-7","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"18_CR147","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","volume":"12","author":"Z Mei","year":"2020","unstructured":"Mei Z, Huang J, Qiao B, Lam AK (2020) Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci 12(1):16. https:\/\/doi.org\/10.1038\/s41368-020-0084-8","journal-title":"Int J Oral Sci"},{"issue":"19","key":"18_CR148","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.Ccr-16-3232","volume":"23","author":"LK Mell","year":"2017","unstructured":"Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA (2017) Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with Locoregionally advanced head and neck carcinoma. Clin Cancer Res 23(19):5696\u20135702. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3232","journal-title":"Clin Cancer Res"},{"key":"18_CR149","doi-asserted-by":"publisher","unstructured":"Menon S, Shin S, Dy G (2016) Advances in cancer immunotherapy in solid tumors. Cancers (Basel) 8(12). https:\/\/doi.org\/10.3390\/cancers8120106","DOI":"10.3390\/cancers8120106"},{"issue":"1","key":"18_CR150","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","volume":"41","author":"\u00d6 Met","year":"2019","unstructured":"Met \u00d6, Jensen KM, Chamberlain CA, Donia M, Svane IM (2019) Principles of adoptive T cell therapy in cancer. Semin Immunopathol 41(1):49\u201358. https:\/\/doi.org\/10.1007\/s00281-018-0703-z","journal-title":"Semin Immunopathol"},{"issue":"11","key":"18_CR151","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1356965","volume":"6","author":"J Michaeli","year":"2017","unstructured":"Michaeli J, Shaul ME, Mishalian I, Hovav AH, Levy L, Zolotriov L, Granot Z, Fridlender ZG (2017) Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF\u03b1 and NO-dependent mechanism, promoting a tumor-supportive environment. Onco Targets Ther 6(11):e1356965. https:\/\/doi.org\/10.1080\/2162402x.2017.1356965","journal-title":"Onco Targets Ther"},{"key":"18_CR152","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-0716-0146-4_8","volume":"2086","author":"F Mo","year":"2020","unstructured":"Mo F, Mamonkin M (2020) Generation of chimeric antigen receptor T cells using Gammaretroviral vectors. Methods Mol Biol 2086:119\u2013130. https:\/\/doi.org\/10.1007\/978-1-0716-0146-4_8","journal-title":"Methods Mol Biol"},{"issue":"Suppl 2","key":"18_CR153","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.4103\/jpbs.Jpbs_31_19","volume":"11","author":"SP Mohan","year":"2019","unstructured":"Mohan SP, Bhaskaran MK, George AL, Thirutheri A, Somasundaran M, Pavithran A (2019) Immunotherapy in oral cancer. J Pharm Bioallied Sci 11(Suppl 2):S107\u2013s111. https:\/\/doi.org\/10.4103\/jpbs.Jpbs_31_19","journal-title":"J Pharm Bioallied Sci"},{"issue":"7","key":"18_CR154","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.12669\/pjms.40.7.8791","volume":"40","author":"SF Mohsin","year":"2024","unstructured":"Mohsin SF (2024) Vaccine a promising immunotherapy option for head and neck cancer patients. Pak J Med Sci 40(7):1578\u20131583. https:\/\/doi.org\/10.12669\/pjms.40.7.8791","journal-title":"Pak J Med Sci"},{"issue":"1","key":"18_CR155","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16(1):7\u201319. https:\/\/doi.org\/10.1038\/nrc.2015.5","journal-title":"Nat Rev Cancer"},{"key":"18_CR156","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.12.035","volume":"76","author":"JD Moy","year":"2017","unstructured":"Moy JD, Moskovitz JM, Ferris RL (2017) Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 76:152\u2013166. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.035","journal-title":"Eur J Cancer"},{"issue":"9","key":"18_CR157","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.4049\/jimmunol.1001323","volume":"185","author":"BH Nelson","year":"2010","unstructured":"Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185(9):4977\u20134982. https:\/\/doi.org\/10.4049\/jimmunol.1001323","journal-title":"J Immunol"},{"issue":"6","key":"18_CR158","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.it.2012.04.006","volume":"33","author":"K Neyt","year":"2012","unstructured":"Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN (2012) Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 33(6):297\u2013305. https:\/\/doi.org\/10.1016\/j.it.2012.04.006","journal-title":"Trends Immunol"},{"issue":"7","key":"18_CR159","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/hed.24406","volume":"38","author":"N Nguyen","year":"2016","unstructured":"Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT (2016) Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck 38(7):1074\u20131084. https:\/\/doi.org\/10.1002\/hed.24406","journal-title":"Head Neck"},{"key":"18_CR160","doi-asserted-by":"publisher","unstructured":"Nisar S, Yousuf P, Masoodi T, Wani NA, Hashem S, Singh M, Sageena G, Mishra D, Kumar R, Haris M, Bhat AA, Macha MA (2021) Chemokine-cytokine networks in the head and neck tumor microenvironment. Int J Mol Sci 22(9). https:\/\/doi.org\/10.3390\/ijms22094584","DOI":"10.3390\/ijms22094584"},{"issue":"2","key":"18_CR161","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151. https:\/\/doi.org\/10.1016\/s1074-7613(00)80089-8","journal-title":"Immunity"},{"issue":"1","key":"18_CR162","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010","journal-title":"Immunity"},{"issue":"5","key":"18_CR163","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim K-H, Fields RC, Strasberg SM, Hawkins WG, DeNardo D et al (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17(5):651\u2013662. https:\/\/doi.org\/10.1016\/S1470-2045(16)00078-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"18_CR164","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2567.2006.02362.x","volume":"118","author":"C Oderup","year":"2006","unstructured":"Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F (2006) Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 118(2):240\u2013249. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02362.x","journal-title":"Immunology"},{"issue":"7","key":"18_CR165","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue Y, Nishikawa H (2019) Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 110(7):2080\u20132089. https:\/\/doi.org\/10.1111\/cas.14069","journal-title":"Cancer Sci"},{"issue":"24","key":"18_CR166","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98(24):13866\u201313871. https:\/\/doi.org\/10.1073\/pnas.231486598","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"18_CR167","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.wjorl.2016.05.009","volume":"2","author":"MO Old","year":"2016","unstructured":"Old MO, Wise-Draper T, Wright CL, Kaur B, Teknos T (2016) The current status of oncolytic viral therapy for head and neck cancer. World J Otorhinolaryngol Head Neck Surg 2(2):84\u201389. https:\/\/doi.org\/10.1016\/j.wjorl.2016.05.009","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"18_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104453","volume":"99","author":"E Orlandi","year":"2019","unstructured":"Orlandi E, Iacovelli NA, Tombolini V, Rancati T, Polimeni A, De Cecco L, Valdagni R, De Felice F (2019) Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncol 99:104453. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104453","journal-title":"Oral Oncol"},{"issue":"6","key":"18_CR169","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison J et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719\u2013734. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005","journal-title":"Cancer Cell"},{"key":"18_CR170","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.oraloncology.2016.08.001","volume":"61","author":"SI Pai","year":"2016","unstructured":"Pai SI, Zandberg DP, Strome SE (2016) The role of antagonists of the PD-1:PD-L1\/PD-L2 axis in head and neck cancer treatment. Oral Oncol 61:152\u2013158. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.08.001","journal-title":"Oral Oncol"},{"issue":"2","key":"18_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229089","volume":"15","author":"X Pang","year":"2020","unstructured":"Pang X, Fan HY, Tang YL, Wang SS, Cao MX, Wang HF, Dai LL, Wang K, Yu XH, Wu JB, Tang YJ, Liang XH (2020) Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS One 15(2):e0229089. https:\/\/doi.org\/10.1371\/journal.pone.0229089","journal-title":"PLoS One"},{"issue":"1","key":"18_CR172","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84\u201388. https:\/\/doi.org\/10.1038\/nm1517","journal-title":"Nat Med"},{"issue":"2","key":"18_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350635","volume":"54","author":"C Patterson","year":"2024","unstructured":"Patterson C, Hazime KS, Zelenay S, Davis DM (2024) Prostaglandin E2 impacts multiple stages of the natural killer cell antitumor immune response. Eur J Immunol 54(2):e2350635. https:\/\/doi.org\/10.1002\/eji.202350635","journal-title":"Eur J Immunol"},{"key":"18_CR174","doi-asserted-by":"publisher","unstructured":"Payne K, Brooks J, Spruce R, Batis N, Taylor G, Nankivell P, Mehanna H (2019) Circulating tumour cell biomarkers in head and neck cancer: current Progress and future prospects. Cancers (Basel) 11(8). https:\/\/doi.org\/10.3390\/cancers11081115","DOI":"10.3390\/cancers11081115"},{"issue":"1","key":"18_CR175","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","volume":"18","author":"B Peltanova","year":"2019","unstructured":"Peltanova B, Raudenska M, Masarik M (2019) Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer 18(1):63. https:\/\/doi.org\/10.1186\/s12943-019-0983-5","journal-title":"Mol Cancer"},{"issue":"7791","key":"18_CR176","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougo\u00fcin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556\u2013560. https:\/\/doi.org\/10.1038\/s41586-019-1906-8","journal-title":"Nature"},{"key":"18_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/16833_2023_157","volume-title":"The evolving concept of viruses and immune system interaction in head and neck neoplasms","author":"F Petrelli","year":"2023","unstructured":"Petrelli F, Malaspina L, Piane RM, Ambrosio MR (2023) The evolving concept of viruses and immune system interaction in head and neck neoplasms. Springer International Publishing, pp 1\u201328. https:\/\/doi.org\/10.1007\/16833_2023_157"},{"issue":"7","key":"18_CR178","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis C, Jones GW, Bombardieri M, Jones SA (2014) Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 14(7):447\u2013462. https:\/\/doi.org\/10.1038\/nri3700","journal-title":"Nat Rev Immunol"},{"key":"18_CR179","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/1471-2407-9-292","volume":"9","author":"D Pretscher","year":"2009","unstructured":"Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G (2009) Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 9:292. https:\/\/doi.org\/10.1186\/1471-2407-9-292","journal-title":"BMC Cancer"},{"issue":"4","key":"18_CR180","doi-asserted-by":"publisher","first-page":"921","DOI":"10.7150\/thno.22182","volume":"8","author":"X Qin","year":"2018","unstructured":"Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X, Shi J, Li Z, Zhang J, Chen W (2018) Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the Osteopontin-NF-kappa B signaling pathway. Theranostics 8(4):921\u2013940. https:\/\/doi.org\/10.7150\/thno.22182","journal-title":"Theranostics"},{"key":"18_CR181","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.omto.2021.01.011","volume":"20","author":"Y Qin","year":"2021","unstructured":"Qin Y, Zheng X, Gao W, Wang B, Wu Y (2021) Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma. Mol Ther Oncolytics 20:342\u2013351. https:\/\/doi.org\/10.1016\/j.omto.2021.01.011","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"18_CR182","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1600-065X.2011.01007.x","volume":"241","author":"SA Quezada","year":"2011","unstructured":"Quezada SA, Peggs KS, Simpson TR, Allison JP (2011) Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 241(1):104\u2013118. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01007.x","journal-title":"Immunol Rev"},{"issue":"6029","key":"18_CR183","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600\u2013603. https:\/\/doi.org\/10.1126\/science.1202947","journal-title":"Science"},{"issue":"11","key":"18_CR184","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q","volume":"91","author":"TE Reichert","year":"2001","unstructured":"Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL (2001) The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91(11):2136\u20132147","journal-title":"Cancer"},{"issue":"5","key":"18_CR185","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/jco.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616\u2013622. https:\/\/doi.org\/10.1200\/jco.2012.44.6112","journal-title":"J Clin Oncol"},{"issue":"15","key":"18_CR186","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi N et al (2016) Association of Pembrolizumab with tumor response and survival among patients with advanced Melanoma. JAMA 315(15):1600\u20131609. https:\/\/doi.org\/10.1001\/jama.2016.4059","journal-title":"JAMA"},{"issue":"3","key":"18_CR187","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00430-010-0151-4","volume":"199","author":"E Ribechini","year":"2010","unstructured":"Ribechini E, Greifenberg V, Sandwick S, Lutz MB (2010) Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 199(3):273\u2013281. https:\/\/doi.org\/10.1007\/s00430-010-0151-4","journal-title":"Med Microbiol Immunol"},{"issue":"6","key":"18_CR188","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA et al (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6):846\u2013859. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.016","journal-title":"Cancer Cell"},{"issue":"12","key":"18_CR189","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/intimm\/13.12.1583","volume":"13","author":"A Rivera","year":"2001","unstructured":"Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y (2001) Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 13(12):1583\u20131593. https:\/\/doi.org\/10.1093\/intimm\/13.12.1583","journal-title":"Int Immunol"},{"issue":"1","key":"18_CR190","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","volume":"22","author":"JP Rodrigo","year":"2024","unstructured":"Rodrigo JP, S\u00e1nchez-Canteli M, Otero-Rosales M, Mart\u00ednez-Camblor P, Hermida-Prado F, Garc\u00eda-Pedrero JM (2024) Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J Transl Med 22(1):135. https:\/\/doi.org\/10.1186\/s12967-024-04937-x","journal-title":"J Transl Med"},{"issue":"1","key":"18_CR191","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229(1):12\u201326. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00770.x","journal-title":"Immunol Rev"},{"issue":"1","key":"18_CR192","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, K\u00fcrten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC (2021) B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun 12(1):3349. https:\/\/doi.org\/10.1038\/s41467-021-23355-x","journal-title":"Nat Commun"},{"issue":"3","key":"18_CR193","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","volume":"23","author":"AT Ruffin","year":"2023","unstructured":"Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC (2023) Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer 23(3):173\u2013188. https:\/\/doi.org\/10.1038\/s41568-022-00531-9","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"18_CR194","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","volume":"110","author":"L Ruggeri","year":"2007","unstructured":"Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110(1):433\u2013440. https:\/\/doi.org\/10.1182\/blood-2006-07-038687","journal-title":"Blood"},{"issue":"10","key":"18_CR195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1055\/a-1901-9214","volume":"101","author":"A Runge","year":"2022","unstructured":"Runge A, Petersson M, Riechelmann H (2022) Oncolytic virotherapy in head and neck cancer. Laryngorhinootologie 101(10):787\u2013796","journal-title":"Laryngorhinootologie"},{"issue":"6","key":"18_CR196","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ijc.32781","volume":"146","author":"N Ryan","year":"2020","unstructured":"Ryan N, Anderson K, Volpedo G, Hamza O, Varikuti S, Satoskar AR, Oghumu S (2020) STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. Int J Cancer 146(6):1717\u20131729. https:\/\/doi.org\/10.1002\/ijc.32781","journal-title":"Int J Cancer"},{"issue":"2","key":"18_CR197","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0973-029x.325257","volume":"25","author":"M Sahu","year":"2021","unstructured":"Sahu M, Suryawanshi H (2021) Immunotherapy: the future of cancer treatment. J Oral Maxillofac Pathol 25(2):371. https:\/\/doi.org\/10.4103\/0973-029x.325257","journal-title":"J Oral Maxillofac Pathol"},{"issue":"6","key":"18_CR198","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M et al (2016) Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22(6):679\u2013684. https:\/\/doi.org\/10.1038\/nm.4086","journal-title":"Nat Med"},{"issue":"6","key":"18_CR199","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.Cir-21-0171","volume":"10","author":"A Samson","year":"2022","unstructured":"Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, da Silva B, Jennings VA, Bendjama K, Stojkowitz N, Lusky M, Prasad KR, Toogood GJ et al (2022) Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients. Cancer Immunol Res 10(6):745\u2013756. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0171","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"18_CR200","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jcms.2019.01.036","volume":"47","author":"EM Santos","year":"2019","unstructured":"Santos EM, Rodrigues de Matos F, Freitas de Morais E, Galv\u00e3o HC, de Almeida Freitas R (2019) Evaluation of Cd8+ and natural killer cells defense in oral and oropharyngeal squamous cell carcinoma. J Craniomaxillofac Surg 47(4):676\u2013681. https:\/\/doi.org\/10.1016\/j.jcms.2019.01.036","journal-title":"J Craniomaxillofac Surg"},{"issue":"5","key":"18_CR201","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.trecan.2018.03.006","volume":"4","author":"RT Santuray","year":"2018","unstructured":"Santuray RT, Johnson DE, Grandis JR (2018) New therapies in head and neck cancer. Trends Cancer 4(5):385\u2013396. https:\/\/doi.org\/10.1016\/j.trecan.2018.03.006","journal-title":"Trends Cancer"},{"issue":"1","key":"18_CR202","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol 96(1):21\u201333. https:\/\/doi.org\/10.1111\/imcb.1003","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"18_CR203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humimm.2012.09.004","volume":"74","author":"D Sathawane","year":"2013","unstructured":"Sathawane D, Kharat RS, Halder S, Roy S, Swami R, Patel R, Saha B (2013) Monocyte CD40 expression in head and neck squamous cell carcinoma (HNSCC). Hum Immunol 74(1):1\u20135. https:\/\/doi.org\/10.1016\/j.humimm.2012.09.004","journal-title":"Hum Immunol"},{"key":"18_CR204","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","volume":"7","author":"C Saut\u00e8s-Fridman","year":"2016","unstructured":"Saut\u00e8s-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC (2016) Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol 7:407. https:\/\/doi.org\/10.3389\/fimmu.2016.00407","journal-title":"Front Immunol"},{"issue":"6","key":"18_CR205","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19(6):307\u2013325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"18_CR206","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA (2019) Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 20(6):724\u2013735. https:\/\/doi.org\/10.1038\/s41590-019-0346-9","journal-title":"Nat Immunol"},{"issue":"2","key":"18_CR207","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive Intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45(2):374\u2013388. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.009","journal-title":"Immunity"},{"issue":"9","key":"18_CR208","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.Ccr-13-2617","volume":"20","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20(9):2433\u20132444. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2617","journal-title":"Clin Cancer Res"},{"key":"18_CR209","doi-asserted-by":"publisher","unstructured":"Schwab M (2011) Encyclopedia of cancer. https:\/\/doi.org\/10.1007\/978-3-642-16483-5","DOI":"10.1007\/978-3-642-16483-5"},{"issue":"7","key":"18_CR210","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/s0092-8674(05)80055-8","volume":"71","author":"RH Schwartz","year":"1992","unstructured":"Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy. Cell 71(7):1065\u20131068. https:\/\/doi.org\/10.1016\/s0092-8674(05)80055-8","journal-title":"Cell"},{"key":"18_CR211","doi-asserted-by":"publisher","unstructured":"Segal NH, Ou S-H, Balmanoukian AS, Massarelli E, Brahmer J, Weiss J, Schoffski P, Antonia SJ, Massard C, Zandberg DP, Maher C, Khleif S, Jin X, Rebelatto M, Steele K, Antal J, Gupta A, Spreafico A (2016) Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Jpn Soc Med Oncol 27. https:\/\/doi.org\/10.1093\/annonc\/mdw376.01","DOI":"10.1093\/annonc\/mdw376.01"},{"issue":"7","key":"18_CR212","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956\u2013965. https:\/\/doi.org\/10.1016\/S1470-2045(16)30066-3","journal-title":"Lancet Oncol"},{"key":"18_CR213","doi-asserted-by":"publisher","unstructured":"Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle JA, Lechien JR, Kindt N, Journe F, Saussez S (2019) Infiltration of FoxP3+ regulatory T cells is a strong and independent prognostic factor in head and neck squamous cell carcinoma. Cancers (Basel) 11(2). https:\/\/doi.org\/10.3390\/cancers11020227","DOI":"10.3390\/cancers11020227"},{"issue":"3","key":"18_CR214","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neo.2015.01.003","volume":"17","author":"M Sen","year":"2015","unstructured":"Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR (2015) JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 17(3):256\u2013264. https:\/\/doi.org\/10.1016\/j.neo.2015.01.003","journal-title":"Neoplasia"},{"issue":"8","key":"18_CR215","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4161\/onci.22009","volume":"1","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Saut\u00e8s-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Onco Targets Ther 1(8):1323\u20131343. https:\/\/doi.org\/10.4161\/onci.22009","journal-title":"Onco Targets Ther"},{"issue":"5","key":"18_CR216","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201(5):723\u2013735. https:\/\/doi.org\/10.1084\/jem.20041982","journal-title":"J Exp Med"},{"issue":"10","key":"18_CR217","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16(10):601\u2013620. https:\/\/doi.org\/10.1038\/s41571-019-0222-4","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 3","key":"18_CR218","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.4103\/2141-9248.141953","volume":"4","author":"P Shilpa","year":"2014","unstructured":"Shilpa P, Kaul R, Bhat S, Sultana N, Pandeshwar P (2014) Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol. Ann Med Health Sci Res 4(Suppl 3):S178\u2013S184. https:\/\/doi.org\/10.4103\/2141-9248.141953","journal-title":"Ann Med Health Sci Res"},{"key":"18_CR219","doi-asserted-by":"publisher","unstructured":"Shurin M, Umansk V, Malyguine A (2014) The tumor immunoenvironment. https:\/\/doi.org\/10.1007\/978-94-007-6217-6","DOI":"10.1007\/978-94-007-6217-6"},{"issue":"1","key":"18_CR220","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coms.2018.09.002","volume":"31","author":"F Sim","year":"2019","unstructured":"Sim F, Leidner R, Bell RB (2019) Immunotherapy for head and neck cancer. Oral Maxillofac Surg Clin North Am 31(1):85\u2013100. https:\/\/doi.org\/10.1016\/j.coms.2018.09.002","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"18_CR221","doi-asserted-by":"publisher","first-page":"61","DOI":"10.33696\/cancerimmunol.5.076","volume":"5","author":"K Singh","year":"2023","unstructured":"Singh K, Gautam PK (2023) Emulating the role of neutrophils in head and neck cancer microenvironment: prognostic role and therapeutic strategies. J Cancer Immunol 5:61","journal-title":"J Cancer Immunol"},{"issue":"3","key":"18_CR222","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12307-014-0147-5","volume":"8","author":"RV Sionov","year":"2015","unstructured":"Sionov RV, Fridlender ZG, Granot Z (2015) The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron 8(3):125\u2013158. https:\/\/doi.org\/10.1007\/s12307-014-0147-5","journal-title":"Cancer Microenviron"},{"key":"18_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102644","volume":"121","author":"D Smussi","year":"2023","unstructured":"Smussi D, Mattavelli D, Paderno A, Gurizzan C, Lorini L, Romani C, Bignotti E, Grammatica A, Ravanelli M, Bossi P (2023) Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy. Cancer Treat Rev 121:102644. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102644","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"18_CR224","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1189\/jlb.0111021","volume":"90","author":"S Solito","year":"2011","unstructured":"Solito S, Bronte V, Mandruzzato S (2011) Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 90(1):31\u201336. https:\/\/doi.org\/10.1189\/jlb.0111021","journal-title":"J Leukoc Biol"},{"issue":"7","key":"18_CR225","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1078-0432.Ccr-12-2426","volume":"19","author":"RM Srivastava","year":"2013","unstructured":"Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, L\u00f3pez-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL (2013) Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19(7):1858\u20131872. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-2426","journal-title":"Clin Cancer Res"},{"issue":"3","key":"18_CR226","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/1078-0432.Ccr-16-0879","volume":"23","author":"RM Srivastava","year":"2017","unstructured":"Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL (2017) CD137 stimulation enhances Cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer. Clin Cancer Res 23(3):707\u2013716. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0879","journal-title":"Clin Cancer Res"},{"issue":"21","key":"18_CR227","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1158\/1078-0432.Ccr-07-1403","volume":"13","author":"L Strauss","year":"2007","unstructured":"Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL (2007) The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13(21):6301\u20136311. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1403","journal-title":"Clin Cancer Res"},{"key":"18_CR228","doi-asserted-by":"publisher","unstructured":"Su\u00e1rez-S\u00e1nchez FJ, Lequerica-Fern\u00e1ndez P, Rodrigo JP, Hermida-Prado F, Su\u00e1rez-Canto J, Rodr\u00edguez-Santamarta T, Dom\u00ednguez-Iglesias F, Garc\u00eda-Pedrero JM, de Vicente JC (2021) Tumor-infiltrating CD20(+) B lymphocytes: significance and prognostic implications in Oral cancer microenvironment. Cancers (Basel) 13(3). https:\/\/doi.org\/10.3390\/cancers13030395","DOI":"10.3390\/cancers13030395"},{"key":"18_CR229","doi-asserted-by":"publisher","unstructured":"Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT (2019) Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 4(7). https:\/\/doi.org\/10.1172\/jci.insight.126853","DOI":"10.1172\/jci.insight.126853"},{"issue":"8","key":"18_CR230","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.jvir.2013.05.040","volume":"24","author":"DY Sze","year":"2013","unstructured":"Sze DY, Reid TR, Rose SC (2013) Oncolytic virotherapy. J Vasc Interv Radiol 24(8):1115\u20131122. https:\/\/doi.org\/10.1016\/j.jvir.2013.05.040","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"18_CR231","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4049\/jimmunol.1601356","volume":"198","author":"V Tahiliani","year":"2017","unstructured":"Tahiliani V, Hutchinson TE, Abboud G, Croft M, Salek-Ardakani S (2017) OX40 cooperates with ICOS to amplify follicular Th cell development and germinal center reactions during infection. J Immunol 198(1):218\u2013228. https:\/\/doi.org\/10.4049\/jimmunol.1601356","journal-title":"J Immunol"},{"issue":"2","key":"18_CR232","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192(2):303\u2013310. https:\/\/doi.org\/10.1084\/jem.192.2.303","journal-title":"J Exp Med"},{"issue":"11","key":"18_CR233","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00262-015-1742-0","volume":"64","author":"H Takahashi","year":"2015","unstructured":"Takahashi H, Sakakura K, Kawabata-Iwakawa R, Rokudai S, Toyoda M, Nishiyama M, Chikamatsu K (2015) Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancer Immunol Immunother 64(11):1407\u20131417. https:\/\/doi.org\/10.1007\/s00262-015-1742-0","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"18_CR234","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/0022034518764416","volume":"97","author":"YS Tan","year":"2018","unstructured":"Tan YS, Sansanaphongpricha K, Prince MEP, Sun D, Wolf GT, Lei YL (2018) Engineering vaccines to reprogram immunity against head and neck cancer. J Dent Res 97(6):627\u2013634. https:\/\/doi.org\/10.1177\/0022034518764416","journal-title":"J Dent Res"},{"issue":"7","key":"18_CR235","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/jco.2010.28.9777","volume":"29","author":"C Tarella","year":"2011","unstructured":"Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mul\u00e9 A, Bosa M, Barbui A, Di Nicola M et al (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814\u2013824. https:\/\/doi.org\/10.1200\/jco.2010.28.9777","journal-title":"J Clin Oncol"},{"issue":"13","key":"18_CR236","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.yexcr.2008.05.018","volume":"314","author":"O Tatti","year":"2008","unstructured":"Tatti O, Vehvil\u00e4inen P, Lehti K, Keski-Oja J (2008) MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res 314(13):2501\u20132514. https:\/\/doi.org\/10.1016\/j.yexcr.2008.05.018","journal-title":"Exp Cell Res"},{"issue":"16","key":"18_CR237","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1158\/0008-5472.Can-11-0993","volume":"71","author":"M Terme","year":"2011","unstructured":"Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Pr\u00e9vost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L (2011) IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 71(16):5393\u20135399. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-0993","journal-title":"Cancer Res"},{"key":"18_CR238","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terr\u00e9n","year":"2019","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J, Zenarruzabeitia O, Borrego F (2019) NK cell metabolism and tumor microenvironment. Front Immunol 10:2278. https:\/\/doi.org\/10.3389\/fimmu.2019.02278","journal-title":"Front Immunol"},{"key":"18_CR239","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","volume":"223","author":"LA Tesmer","year":"2008","unstructured":"Tesmer LA, Lundy SK, Sarkar S, Fox DA (2008) Th17 cells in human disease. Immunol Rev 223:87\u2013113. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00628.x","journal-title":"Immunol Rev"},{"issue":"11","key":"18_CR240","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s11427-018-9411-4","volume":"61","author":"D Ti","year":"2018","unstructured":"Ti D, Niu Y, Wu Z, Fu X, Han W (2018) Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Sci China Life Sci 61(11):1320\u20131332. https:\/\/doi.org\/10.1007\/s11427-018-9411-4","journal-title":"Sci China Life Sci"},{"issue":"5","key":"18_CR241","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541\u2013547. https:\/\/doi.org\/10.1016\/1074-7613(95)90125-6","journal-title":"Immunity"},{"issue":"8","key":"18_CR242","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M (2022) Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630\u20131639. https:\/\/doi.org\/10.1038\/s41591-022-01897-x","journal-title":"Nat Med"},{"issue":"6","key":"18_CR243","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression \u2013 implications for anticancer therapy. Nat Rev Clin Oncol 16(6):356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"18_CR244","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/jci80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015) Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125(9):3365\u20133376. https:\/\/doi.org\/10.1172\/jci80006","journal-title":"J Clin Invest"},{"issue":"2","key":"18_CR245","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hed.24561","volume":"39","author":"C Valero","year":"2017","unstructured":"Valero C, Pardo L, L\u00f3pez M, Garc\u00eda J, Camacho M, Quer M, Le\u00f3n X (2017) Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer. Head Neck 39(2):219\u2013226. https:\/\/doi.org\/10.1002\/hed.24561","journal-title":"Head Neck"},{"issue":"3","key":"18_CR246","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"A van Elsas","year":"1999","unstructured":"van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355\u2013366. https:\/\/doi.org\/10.1084\/jem.190.3.355","journal-title":"J Exp Med"},{"issue":"8","key":"18_CR247","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498. https:\/\/doi.org\/10.1038\/s41577-020-00490-y","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"18_CR248","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","volume":"18","author":"S Verheyden","year":"2004","unstructured":"Verheyden S, Bernier M, Demanet C (2004) Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18(12):2002\u20132007. https:\/\/doi.org\/10.1038\/sj.leu.2403525","journal-title":"Leukemia"},{"issue":"12","key":"18_CR249","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1002\/cncr.23442","volume":"112","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J (2008a) Overview of the efficacy of cetuximab in recurrent and\/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112(12):2710\u20132719. https:\/\/doi.org\/10.1002\/cncr.23442","journal-title":"Cancer"},{"issue":"11","key":"18_CR250","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008b) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"issue":"8","key":"18_CR251","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2767-9764.CRC-24-0150","volume":"4","author":"R Vernet","year":"2024","unstructured":"Vernet R, Fernandez E, Migliorini D, Ancrenaz V, Charrier E, Belkouch M-C, Von Rohr O, Urwyler M, De Vito C, Renaux J, Villard J, Rubin O, Grogg J, Mach N (2024) A first-in-human phase I clinical study with MVX-ONCO-1, a personalized active immunotherapy, in patients with advanced solid tumors. Cancer Res Commun 4(8):2089\u20132100. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0150","journal-title":"Cancer Res Commun"},{"issue":"3","key":"18_CR252","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/s0002-9610(97)00139-6","volume":"174","author":"JT Vetto","year":"1997","unstructured":"Vetto JT, Lum S, Morris A, Sicotte M, Davis J, Lemon M, Weinberg A (1997) Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg 174(3):258\u2013265. https:\/\/doi.org\/10.1016\/s0002-9610(97)00139-6","journal-title":"Am J Surg"},{"issue":"6","key":"18_CR253","first-page":"1287","volume":"59","author":"A von Leoprechting","year":"1999","unstructured":"von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC (1999) Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59(6):1287\u20131294","journal-title":"Cancer Res"},{"issue":"7","key":"18_CR254","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/jco.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O\u2019Dwyer PJ, Running KL, Huhn RD, Antonia SJ (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876\u2013883. https:\/\/doi.org\/10.1200\/jco.2006.08.3311","journal-title":"J Clin Oncol"},{"issue":"4","key":"18_CR255","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/blood-2009-08-240325","volume":"116","author":"L Vujanovic","year":"2010","unstructured":"Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH (2010) Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood 116(4):575\u2013583. https:\/\/doi.org\/10.1182\/blood-2009-08-240325","journal-title":"Blood"},{"issue":"4","key":"18_CR256","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4161\/onci.19788","volume":"1","author":"L Vujanovic","year":"2012","unstructured":"Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH (2012) Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8\/IL-8 and CXCL10\/IP-10. Onco Targets Ther 1(4):448\u2013457. https:\/\/doi.org\/10.4161\/onci.19788","journal-title":"Onco Targets Ther"},{"key":"18_CR257","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2019.00014","volume":"10","author":"L Vujanovic","year":"2019","unstructured":"Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH (2019) CD56(dim) CD16(\u2212) natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-\u03b1. Front Immunol 10:14. https:\/\/doi.org\/10.3389\/fimmu.2019.00014","journal-title":"Front Immunol"},{"issue":"9","key":"18_CR258","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/ijc.29962","volume":"138","author":"S Wagner","year":"2016","unstructured":"Wagner S, Wittekindt C, Reuschenbach M, Hennig B, Thevarajah M, W\u00fcrdemann N, Prigge ES, von Knebel Doeberitz M, Dreyer T, Gattenl\u00f6hner S, Klussmann JP (2016) CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma. Int J Cancer 138(9):2263\u20132273. https:\/\/doi.org\/10.1002\/ijc.29962","journal-title":"Int J Cancer"},{"key":"18_CR259","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/542851","volume":"2012","author":"A Wallecha","year":"2012","unstructured":"Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J (2012) Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol 2012:542851. https:\/\/doi.org\/10.1155\/2012\/542851","journal-title":"J Oncol"},{"key":"18_CR260","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fonc.2019.01084","volume":"9","author":"HC Wang","year":"2019","unstructured":"Wang HC, Chan LP, Cho SF (2019) Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol 9:1084. https:\/\/doi.org\/10.3389\/fonc.2019.01084","journal-title":"Front Oncol"},{"key":"18_CR261","doi-asserted-by":"publisher","unstructured":"Wang Z, Sun P, Li Z, Xiao S (2023) Clinical advances and future directions of oncolytic Virotherapy for head and neck cancer. Cancers (Basel) 15(21). https:\/\/doi.org\/10.3390\/cancers15215291","DOI":"10.3390\/cancers15215291"},{"issue":"1","key":"18_CR262","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"18_CR263","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.Ccr-14-1711","volume":"21","author":"DT Weed","year":"2015","unstructured":"Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borrello I, Serafini P (2015) Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21(1):39\u201348. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1711","journal-title":"Clin Cancer Res"},{"key":"18_CR264","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2017.00387","volume":"8","author":"S Weil","year":"2017","unstructured":"Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, M\u00fcller-Runte A, Lampe K, Beutner D, Quaas A, Schubert R, Herrmann E, Steinle A, Koehl U, Walter L, von Bergwelt-Baildon MS, Koch J (2017) Natural killer group 2D ligand depletion reconstitutes natural killer cell Immunosurveillance of head and neck squamous cell carcinoma. Front Immunol 8:387. https:\/\/doi.org\/10.3389\/fimmu.2017.00387","journal-title":"Front Immunol"},{"issue":"6","key":"18_CR265","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1201920","volume":"190","author":"K Wejksza","year":"2013","unstructured":"Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, Becker K, Biragyn A (2013) Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor \u03b1. J Immunol 190(6):2575\u20132584. https:\/\/doi.org\/10.4049\/jimmunol.1201920","journal-title":"J Immunol"},{"issue":"6","key":"18_CR266","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492\u2013499. https:\/\/doi.org\/10.1038\/ni.2035","journal-title":"Nat Immunol"},{"issue":"8","key":"18_CR267","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486\u2013499. https:\/\/doi.org\/10.1038\/nri3862","journal-title":"Nat Rev Immunol"},{"issue":"5899","key":"18_CR268","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271\u2013275. https:\/\/doi.org\/10.1126\/science.1160062","journal-title":"Science"},{"issue":"8","key":"18_CR269","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11912-020-00938-3","volume":"22","author":"NE Wondergem","year":"2020","unstructured":"Wondergem NE, Nauta IH, Muijlwijk T, Leemans CR, van de Ven R (2020) The immune microenvironment in head and neck squamous cell carcinoma: on subsets and subsites. Curr Oncol Rep 22(8):81. https:\/\/doi.org\/10.1007\/s11912-020-00938-3","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"18_CR270","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","volume":"26","author":"ALA Wong","year":"2017","unstructured":"Wong ALA, Hirpara JL, Pervaiz S, Eu JQ, Sethi G, Goh BC (2017) Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs 26(8):883\u2013887. https:\/\/doi.org\/10.1080\/13543784.2017.1351941","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"18_CR271","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","volume":"7","author":"L Wu","year":"2019","unstructured":"Wu L, Mao L, Liu J-F, Chen L, Yu G-T, Yang L-L, Wu H, Bu L-L, Kulkarni AB, Zhang W-F, Sun Z-J (2019) Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res 7(10):1700\u20131713. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0725","journal-title":"Cancer Immunol Res"},{"key":"18_CR272","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.molimm.2020.01.008","volume":"119","author":"H Wu","year":"2020","unstructured":"Wu H, Xia L, Jia D, Zou H, Jin G, Qian W, Xu H, Li T (2020) PD-L1(+) regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis. Mol Immunol 119:83\u201391. https:\/\/doi.org\/10.1016\/j.molimm.2020.01.008","journal-title":"Mol Immunol"},{"issue":"5","key":"18_CR273","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.Cd-15-1408","volume":"6","author":"X Xiao","year":"2016","unstructured":"Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, Chen DP, Zhao XY, Zhao Q, Li XF, Liu CL, Zheng L, Kuang DM (2016) PD-1hi identifies a novel regulatory B-cell population in human Hepatoma that promotes disease progression. Cancer Discov 6(5):546\u2013559. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-1408","journal-title":"Cancer Discov"},{"key":"18_CR274","doi-asserted-by":"publisher","unstructured":"Xu J (2020) Regulation of cancer immune checkpoints. Adva Exp Med Biol 1248. https:\/\/doi.org\/10.1007\/978-981-15-3266-5","DOI":"10.1007\/978-981-15-3266-5"},{"issue":"8","key":"18_CR275","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1002\/hed.25737","volume":"41","author":"R Yasumatsu","year":"2019","unstructured":"Yasumatsu R, Wakasaki T, Hashimoto K, Nakashima K, Manako T, Taura M, Matsuo M, Nakagawa T (2019) Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. Head Neck 41(8):2610\u20132618. https:\/\/doi.org\/10.1002\/hed.25737","journal-title":"Head Neck"},{"issue":"1","key":"18_CR276","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajpath.2012.08.041","volume":"182","author":"J Ye","year":"2013","unstructured":"Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182(1):10\u201320. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.041","journal-title":"Am J Pathol"},{"issue":"3","key":"18_CR277","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.4049\/jimmunol.1501293","volume":"196","author":"RH Younis","year":"2016","unstructured":"Younis RH, Han KL, Webb TJ (2016) Human head and neck squamous cell carcinoma-associated Semaphorin 4D induces expansion of myeloid-derived suppressor cells. J Immunol 196(3):1419\u20131429. https:\/\/doi.org\/10.4049\/jimmunol.1501293","journal-title":"J Immunol"},{"issue":"9","key":"18_CR278","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41419-018-0927-9","volume":"9","author":"L Yu","year":"2018","unstructured":"Yu L, Yang F, Zhang F, Guo D, Li L, Wang X, Liang T, Wang J, Cai Z, Jin H (2018) CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. Cell Death Dis 9(9):905. https:\/\/doi.org\/10.1038\/s41419-018-0927-9","journal-title":"Cell Death Dis"},{"issue":"1","key":"18_CR279","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/abt\/tby002","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, AlDeghaither D, O\u2019Connell A, Weiner LM (2018) Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 1(1):7\u201312. https:\/\/doi.org\/10.1093\/abt\/tby002","journal-title":"Antib Ther"},{"issue":"9","key":"18_CR280","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"N Engl J Med"},{"issue":"3","key":"18_CR281","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo.2016.3616","volume":"49","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W (2016) Neutrophils in cancer development and progression: roles, mechanisms, and implications (review). Int J Oncol 49(3):857\u2013867. https:\/\/doi.org\/10.3892\/ijo.2016.3616","journal-title":"Int J Oncol"},{"issue":"2","key":"18_CR282","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1084\/jem.20091777","volume":"207","author":"D Zotos","year":"2010","unstructured":"Zotos D, Coquet JM, Zhang Y, Light A, D\u2019Costa K, Kallies A, Corcoran LM, Godfrey DI, Toellner KM, Smyth MJ, Nutt SL, Tarlinton DM (2010) IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 207(2):365\u2013378. https:\/\/doi.org\/10.1084\/jem.20091777","journal-title":"J Exp Med"},{"issue":"22","key":"18_CR283","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1158\/0008-5472.CAN-04-1987","volume":"64","author":"L Zou","year":"2004","unstructured":"Zou L, Barnett B, Safah H, LaRussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W (2004) Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12\/CXCR4 signals. Cancer Res 64(22):8451\u20138455. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1987","journal-title":"Cancer Res"}],"container-title":["Advances in Experimental Medicine and Biology","Oral Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-03176-1_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:29:22Z","timestamp":1784294962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-03176-1_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"ISBN":["9783032031754","9783032031761"],"references-count":283,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-03176-1_18","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"13 November 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}